Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin
21 Jul, 2017 | 17:51h | UTCAntiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis – Stroke (link to abstract – $ for full-text)
Commentary: Adjusting Antiplatelet Regimen Could Decrease Risk For Stroke Patients on Aspirin Monotherapy – American College of Cardiology, Latest in Cardiology (free)
Meta-analysis of cohort studies: in patients who experienced an ischemic stroke or transient ischemic attack while on aspirin monotherapy, the addition of or a switch to another antiplatelet agent, versus aspirin monotherapy, was associated with a 32 percent reduction in the risk of major adverse cardiovascular events (HR 0.68; 0.54–0.85) and 30 percent reduction in recurrent strokes (HR, 0.70; 0.54–0.92). Additional randomized trials would better clarify the best antiplatet regimen for these patients.